<b>Conclusion:</b> Beyond HK2 expression, <sup>18</sup>F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and hematopoietic stem cell transplantation (HSCT), as well as disease progression and progression-free survival in multiple myeloma (MM) patients, thus becoming a tool of personalized medicine.
We evaluated differences in density and <sup>18</sup>F-FDG PET/MRI features of lytic bone lesions (LBLs) identified by whole-body low-dose CT (WB-LDCT) in patients affected by newly diagnosed multiple myeloma (MM).
Pretreatment <sup>18</sup>F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.
Progression to MM occurred in 29 patients with an average of 18.3 months; MM was more likely to develop in patients with bone plasmacytoma and in patients with 18F-FDG avid lesion.
<sup>18</sup> F-FDG PET/CT in combination with clinical parameters provided an accurate and simple method for risk stratification of patients with newly diagnosed MM.
WB-MRI is more sensitive than <sup>18</sup>F-FDG PET/CT in the diagnosis of MM before treatment; however, <sup>18</sup>F-FDG PET/CT is more specific than WB-MRI in detecting residual involvement in treated patients.
Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.
Despite the significant upgrading in recent years of the role of <sup>18</sup>F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers.
An observational study was set up to assess the feasibility of [<sup>18</sup>F]FPRGD<sub>2</sub> PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [<sup>18</sup>F]NaF/[<sup>18</sup>F]FDG PET/CT images.
Here we present a case of a multiple myeloma patient with muscle involvement found by F-FDG PET/CT, which is sensitive in detecting extramedullary lesions of multiple myeloma.
The vulvar lesion was negative at the F-FDG PET/CT but showed high uptake of C-MET; focal uptake of both F-FDG and C-MET was shown within the muscles of the left leg, histologically confirmed as extramedullary relapse of MM.
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.
[<sup>68</sup>Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [<sup>18</sup>F]FDG and laboratory values.